课题基金 / 基金详情

Establishment of novel differentiation-inducing therapy for leukemia with hematopoietic growth factors and arsenic trioxide

Establishment of novel differentiation-inducing therapy for leukemia with hematopoietic growth factors and arsenic trioxide
造血生长因子和三氧化二砷新型白血病诱导分化疗法的建立
批准号:
13671083
负责人:
KIZAKI Masahiro
金额:
$2.62万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

KIZAKI Masahiro的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Arsenic trioxide (As_2O_3) effectively induces clinical remission via apoptosis in related acute promyelocytic leukemia (APL). However, because this new anti-leukemic drug is also considered to be a poison, its possible adverse effects are a highly important issue related to its clinical use. We investigated both in vitro and in vivo, the effects of a combination of As_2O_3 and GM-CSF as a novel therapeutic approach for the treatment of acute leukemia. Treatment of acute lmyeloid eukemic cells with a combination of As_2O_3 and GM-CSF for 4 days resulted in differentiation, but not apoptosis, to mature granulocytes. GM-CSF was found to be associated with increased tyrosine phosphorylation of Jak2 kinase in acute promyelocytic leukemia (APL) cells, and a specific inhibitor of Jak2, AG490, completely blocked the ability of GM-CSF to prevent apoptosis and induce differentiation of As_2O_3-treated APL cells. In in vivo analysis, As_2O_3 induced differentiation of APL cells in a retinoic aci … More d-resistant APL model of human GM-CSF-producing transgenic SCID mice that had a high level of human GM-CSF in their sera. In contrast, As_2O_3 alone diminished tumors in retinoic acid-resistant APL UF-1 cells transplanted into NOD/SCID mice via induction of apoptosis.We also performed the experiments using TGF-β superfamily cytokines including bone morphogenetic protein(BMP) and activin A for inducing apoptosis of leukemia and myeloma cells. BMP induces apoptosis of human myeloma cell lines and primary samples. BMP caused cell cycle arrest in the G1 phase which was associated with accumulation of p21 and p27, and the subsequent apoptosis of myeloma cells. BMP also induced down-regulation of Bcl-X_L through the inactivation of STAT3, resulting in the induction of apoptosis of myeloma cells. In addition, activin A induced rapid apoptosis of chronic myeloid leukemia (CML) cells via transient induction of Mcl-1. These results suggest that cytokines may have a potential to be novel therapeutic agents for treatment in patients with leukemia and myeloma. Especially, a combination of As_2O_3 and GM-CSF appears to be a novel differentiation-inducing therapy for APL with less toxic effects. Less
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
Takayama N, Kizaki M, et al.: "A novel mutation of PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to RA in APL"Exp. Hematol.. 29. 864-872 (2001)
Takayama N、Kizaki M 等人:“PML/RARα 嵌合基因的一种新突变表现出显着降低的配体结合活性,并赋予 Hematol 获得性 RA 抗性”Exp. 29. 864-872 (2001)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Fukuchi Y, Kizaki M, et al: "Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells"Oncogene. 20(6). 704-713 (2001)
Fukuchi Y、Kizaki M 等人:“Mcl-1,一种早期诱导分子,调节激活素 A 诱导的 CML 细胞凋亡和分化”癌基因。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hirano T, Kizaki M, Kato K, et al.: "Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid"Leuk. Res.. 26(12). 1097-1103 (2002)
Hirano T、Kizaki M、Kato K 等人:“急性早幼粒细胞白血病 NB4 细胞的贝他汀对全反式视黄酸的敏感性增强”Leuk。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Suwanai H, Matsushita H, Kizaki M, et al.: "A novel therapeutic technology of specific RNA inhibition for APL : Improved design of maxizymes against PML/RARα mRNA"Int. J. Oncol.. 20. 127-130 (2002)
Suwanai H、Matsushita H、Kizaki M 等人:“APL 特异性 RNA 抑制的新颖治疗技术:针对 PML/RARα mRNA 的大酶的改进设计”Int. J. Oncol.. 20. 127-130 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
10
    Development of new therapeutic approach for multiple myeloma targeted against biological properties of bone marrow microenvironment
    • 批准号:
      24591409
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.49万
    • 财政年份:
      2012
    • 负责人:
      KIZAKI Masahiro
    • 依托单位:
    Development of novel molecular-targeting therapy for multiple myeloma against its progenitor cells
    • 批准号:
      21591219
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2009
    • 负责人:
      KIZAKI Masahiro
    • 依托单位:
    Regulation of human leukemic stem cell by reactive oxygen species (ROS) and its therapeutic applications in the clinics
    • 批准号:
      19591137
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      KIZAKI Masahiro
    • 依托单位:
    Establishment of new molecular-targeted therapy for leukemia mediated through HIF-1 regulation by ROS
    • 批准号:
      17591010
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2005
    • 负责人:
      KIZAKI Masahiro
    • 依托单位:
    海外基金